Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript Summary
Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript Summary
Operating loss for the nine months ending September 2024 increased to $22.8 million from $19 million, with a third-quarter net loss of $24 million.The following is a summary of the Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript:
以下是Senseonics Holdings, Inc.（SENS）2024年第三季度業績會議呼叫成績單總結：
Financial Performance:
財務表現:
Q3 2024 net revenue was $4.3 million, a decrease from $6.1 million in the previous year, primarily due to inventory adjustments for the Eversense 365 launch.
Gross loss for Q3 2024 was $4.1 million, down from a gross profit of $1.2 million year-over-year, influenced by one-time charges linked to the new product transition.
Operating loss for the nine months ending September 2024 increased to $22.8 million from $19 million, with a third-quarter net loss of $24 million.
2024年第三季度淨營業收入爲$430萬，較去年$610萬有所下降，主要是由於Eversense 365推出時的庫存調整。
2024年第三季度毛利潤虧損爲$410萬，較去年同期$120萬的毛利潤下降，主要是由於與新產品過渡相關的一次性費用影響。
2024年9月底九個月的營業虧損從$1900萬增加到$2280萬，第三季度淨虧損爲$2400萬。
Business Progress:
業務進展：
FDA approval of Eversense 365, a one-year continuous glucose monitor, significantly builds on product advancement.
Launch of Eversense 365 with early positive feedback and strong healthcare provider adoption.
Strategic moves including acquisition of Eversense Insertion Network assets and plans for cost reductions in 2025 to enhance financial stability.
Progress on the development of next-generation sensors, Gemini and Freedom, which offer battery power and direct phone communication respectively.
FDA批准Eversense 365，一款爲期一年的持續血糖監測儀，極大地推動了產品進展。
Eversense 365推出時得到了積極的初步反饋和醫療保健提供者的積極採納。
戰略舉措包括收購Eversense插入網絡資產和計劃於2025年進行成本削減，以增強財務穩定性。
下一代傳感器Gemini和Freedom的開發進展順利，分別提供電池供電和直接電話通信。
Opportunities:
機會：
Eversense 365 coverage by nearly all U.S. insurers and Medicare, enhancing accessibility.
Expanded partnerships with health systems, such as Mercy, expected to improve patient outcomes and reduce care costs.
Anticipated revenue growth from Eversense 365 in 2025 with improved unit economics.
Eversense 365已覆蓋幾乎所有美國保險公司和醫療保險，提高了可及性。
與諸如Mercy等衛生系統的合作伙伴關係擴大，預計將改善患者結果並降低護理成本。
預計Eversense 365將於2025年實現營業收入增長，並改善單位經濟學。
Risks:
風險：
Transitioning to Eversense 365 impacts short-term revenue due to inventory management and product switchovers, particularly affecting Q3 and possibly extending into early 2025.
轉向Eversense 365影響短期營業收入，由於庫存管理和產品切換，特別影響第三季度，可能延伸至2025年初。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
